Clinical trial · Observational
An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer
A Patient Cohort With Locally Advanced or Metastatic Non-small Cell Lung Cancer Treated With Tarceva (Erlotinib) Monotherapy and Not Progressing After at Least 9 Months
NCT01488331CI-TRIAL-00024695completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective, multi-center, observational study will assess the progression-free survival and safety of patients with locally advanced or metastatic non-small cell lung cancer treated with Tarceva (erlotinib) and not disease progressing after at least 9 months. Data will be collected for 24 months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Squamous Non-Small Cell Lung Cancer | Lung Non-Squamous Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Cohort
Primary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- 24 months
Secondary outcomes (5)
- measure
- Best treatment response
- timeFrame
- 24 months
- measure
- Overall survival
- timeFrame
- 24 months
- measure
- Safety (incidence of adverse events)
- timeFrame
- 24 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients, \>/=18 years of age * Diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC, stage III/IV) * Treatment with Tarceva monotherapy and not progressing after at least 9 months at the date of study start Exclusion Criteria: * Not agreeing to be followed-up (for a maximum of 24 months)
References
Publications (0)
Data not yet available
No reference posted for this study.